Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
RET 5979 XL-999 CHEMBL3545285 DrugBank
RET 5979 QUIZARTINIB CHEMBL576982 inhibitor GuideToPharmacologyInteractions, ChemblInteractions
RET 5979 NINTEDANIB CHEMBL502835 CGI
RET 5979 CETUXIMAB CHEMBL1201577 CKB 27149458
RET 5979 ALECTINIB HYDROCHLORIDE CHEMBL3707320 inhibitor ChemblInteractions
RET 5979 SORAFENIB TOSYLATE CHEMBL1200485 inhibitor ChemblInteractions
RET 5979 SUNITINIB MALATE CHEMBL1567 inhibitor ChemblInteractions
RET 5979 VANDETANIB CHEMBL24828 inhibitor MyCancerGenomeClinicalTrial, TTD, ClearityFoundationClinicalTrial, TdgClinicalTrial, MyCancerGenome, CIViC, GuideToPharmacologyInteractions, OncoKB, DoCM, DrugBank, ChemblInteractions, CKB, TALC, CGI 23533264, 23584301, 25366691, 2015, 8007, 17, 20065189, 22025146, 10592235, 23578175, 23991695, 23154560, 26686064, 27803005, 27825616, 19029224, 15184865, 28447912, 25122427, 27683183, 25157968, 23056499, 20943719, 21470995, 21422803, 11351254, 20368568, 21455200, 18073307, 19255327, 20847059, 9839497, 9681850, 18541894
RET 5979 SUNITINIB CHEMBL535 inhibitor NCI, GuideToPharmacologyInteractions, TALC, CIViC, CKB, TdgClinicalTrial, MyCancerGenome, TEND, CGI, DoCM 16849418, 20696054, 27149458, 28447912, 25157968, 20065189, 22025146, 23056499, 20943719, 21470995, 21422803, 11351254, 20368568, 21455200, 18073307, 19255327, 20847059, 9839497, 9681850, 18541894
RET 5979 LINIFANIB CHEMBL223360 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions
RET 5979 ENMD-2076 CHEMBL482968 TdgClinicalTrial
RET 5979 LENVATINIB CHEMBL1289601 inhibitor TALC, CKB, CIViC 27496134, 25295214
RET 5979 CABOZANTINIB CHEMBL2105717 antagonist, inhibitor TALC, MyCancerGenome, OncoKB, CKB, CGI, CIViC, DrugBank, MyCancerGenomeClinicalTrial, FDA 21606412, 23533264, 23584301, 25366691, 2015, 8007, 17, 27825636, 27525386, 28447912, 23705946
RET 5979 SORAFENIB CHEMBL1336 inhibitor TTD, CIViC, DrugBank, NCI, GuideToPharmacologyInteractions, MyCancerGenome, CKB 20368568, 17016424, 15466206, 16507829, 17664273
RET 5979 AMUVATINIB CHEMBL2103851 inhibitor TALC, MyCancerGenome, TdgClinicalTrial, DrugBank
RET 5979 AST-487 CHEMBL574738 inhibitor GuideToPharmacologyInteractions, ChemblInteractions, CIViC 23828865
RET 5979 LUCITANIB CHEMBL2220486 inhibitor GuideToPharmacologyInteractions
RET 5979 TAMATINIB CHEMBL475251 inhibitor GuideToPharmacologyInteractions
RET 5979 DOVITINIB CHEMBL522892 ClearityFoundationClinicalTrial, CKB 25103625
RET 5979 AZD-1480 CHEMBL1231124 CKB, CIViC 23056499
RET 5979 EVEROLIMUS CHEMBL1908360 CKB 26294908, 27683183
RET 5979 CEP-2563 CHEMBL3545332 inhibitor ChemblInteractions
RET 5979 CHEMBL306380 CHEMBL306380 DrugBank 10592235
RET 5979 PONATINIB CHEMBL1171837 inhibitor TALC, CKB, GuideToPharmacologyInteractions, CIViC, DrugBank, MyCancerGenomeClinicalTrial 23526464, 27496134, 23811235, 25122427
RET 5979 CEP-11981 CHEMBL2010872 inhibitor GuideToPharmacologyInteractions
RET 5979 AT-9283 CHEMBL495727 inhibitor TALC
RET 5979 IMATINIB CHEMBL941 TdgClinicalTrial, TEND
RET 5979 INK-128 CHEMBL3545056 CIViC 23828865
RET 5979 LESTAURTINIB CHEMBL603469 inhibitor ChemblInteractions
RET 5979 GENISTEIN CHEMBL44 NCI 12490842
RET 5979 PHORBOL MYRISTATE ACETATE CHEMBL279115 NCI 7867726
RET 5979 REGORAFENIB CHEMBL1946170 inhibitor TALC, MyCancerGenome, CKB, ChemblInteractions, DrugBank, MyCancerGenomeClinicalTrial 21170960
RET 5979 CHEMBL126955 CHEMBL126955 NCI 15302866
RET 5979 MOTESANIB CHEMBL572881 inhibitor TALC, MyCancerGenome, CKB, ChemblInteractions, CIViC 21422803
RET 5979 DEXAMETHASONE CHEMBL384467 NCI 10947080
RET 5979 TRETINOIN CHEMBL38 NCI 7867726
RET 5979 CEP-32496 CHEMBL2029988 inhibitor CKB, ChemblInteractions 28011461
RET 5979 CHEMBL1213492 CHEMBL1213492 NCI 12123817
RET 5979 ALECTINIB CHEMBL1738797 CKB, CIViC 27544060

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
RET rs1799939 A imatinib dosage no No significant association between genotype and chance of requiring an imatinib dose reduction. Allele A is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G. 30713339 1450933585